Vaccination for rheumatic diseases: Current issues (based on ACR guidelines)
https://doi.org/10.47360/1995-4484-2023-151-157
Abstract
In modern rheumatology, comorbid infections have a significant impact on morbidity and mortality, especially in immuno-inflammatory rheumatic diseases (IIRD). One of the ways to solve this problem is the study and active use of various vaccines. This article analyzes the recommendations for vaccination of patients with acute respiratory infections, proposed in 2022 by experts of the American College of Rheumatology (ACR). The safety and immunogenicity of vaccination associated with the prevention of various infections in patients with IVR are discussed. It is emphasized that the decision to suspend taking the drug before or after vaccination should be made taking into account the existing IIRD, its activity and the risk of vaccine-controlled infection. A key component of any vaccination strategy (especially for conditional recommendations) is decision-making together with the patient. The main directions of future research on the problem under consideration are outlined.
About the Authors
B. S. Belov
V.A. Nasonova Research Institute of Rheumatology
Russian Federation
Russian Federation
115522, Moscow, Kashirskoye Highway, 34A
N. V. Muravyeva
V.A. Nasonova Research Institute of Rheumatology
Russian Federation
Russian Federation
115522, Moscow, Kashirskoye Highway, 34A
E. L. Nasonov
V.A. Nasonova Research Institute of Rheumatology; I.M. Sechenov First Moscow State Medical University of the Ministry of Health Care of Russian Federation (Sechenov University)
Russian Federation
Russian Federation
115522, Moscow, Kashirskoye Highway, 34A;
119991, Moscow, Trubetskaya str., 8, building 2
References
1. Bass AR, Chakravarty E, Akl EA, Bingham CO, Calabrese L, Cappelli LC, et al. 2022 American College of Rheumatology guideline for vaccinations in patients with rheumatic and musculoskeletal diseases. Arthritis Rheumatol. 2023;75(3):333-348. doi: 10.1002/art.42386
2. Centers for Disease Control and Prevention. Advisory Committee on Immunization Practices (ACIP) recommendations. URL: https://www.cdc.gov/vaccines/acip/recommendations.html (Accessed: 10th January 2023).
3. Kimberlin DW, Barnett ED, Lynfield R (eds). Red book: 2021–2024 report of the Committee on Infectious Diseases; 32nd ed. Itasca (IL):American Academy of Pediatrics;2021.
4. Curtis JR, Johnson SR, Anthony DD, Arasaratnam RJ, Baden LR, Bass AR, et al. American College of Rheumatology guidance for COVID-19 vaccination in patients with rheumatic and musculoskeletal diseases: Version 5. Arthritis Rheumatol. 2023;75(1):E1-E16. doi: 10.1002/art.42372
5. Bower H, Frisell T, Di Giuseppe D, Delcoigne B, Askling J. Influenza outcomes in patients with inflammatory joint diseases and DMARDs: How do they compare to those of COVID-19? Ann Rheum Dis. 2022;81(3):433-439. doi: 10.1136/annrheumdis-2021-221461
6. Bukhanova D, Belov B, Tarasova G, Erdes S, Dubinina T, Lukina G, et al. Assessment of efficacy and safety of a trivalent splitvirus influenza vaccine in patients with rheumatic diseases. Ann Rheum Dis. 2018;77(Suppl 2):1060-1061. doi: 10.1136/annrheumdis-2018-eular.1500
7. Stapleton JT, Wagner N, Tuetken R, Bellamy AR, Hill H, Kim S, et al. High dose trivalent influenza vaccine compared to standard dose vaccine in patients with rheumatoid arthritis receiving TNF-alpha inhibitor therapy and healthy controls: Results of the DMID 10-0076 randomized clinical trial. Vaccine. 2020;38(23):3934-3941. doi: 10.1016/j.vaccine.2020.04.002
8. Colmegna I, Useche ML, Rodriguez K, McCormack D, Alfonso G, Patel A, et al. Immunogenicity and safety of high-dose versus standard-dose inactivated influenza vaccine in rheumatoid arthritis patients: A randomised, double-blind, active-comparator trial. Lancet Rheumatol. 2020;1:14-23. doi: 10.1016/S2665-9913(19)30094-3
9. Watad A, Bragazzi NL, McGonagle D, Adawi M, Bridgewood C, Damiani G, et al. Autoimmune/inflammatory syndrome induced by adjuvants (ASIA) demonstrates distinct autoimmune and autoinflammatory disease associations according to the adjuvant subtype: Insights from an analysis of 500 cases. Clin Immunol. 2019;203:1-8. doi: 10.1016/j.clim.2019.03.007
10. Bukhanova DV, Belov BS, Tarasova GM, Soloviev SK, Ananyeva LP, Popkova TV, et al. Comorbid infections in rheumatic diseases (according to FSBI RIR named after V.A. Nasonova). Medical Council. 2019;(9):86-91 (In Russ.). doi: 10.21518/2079-701X-2019-9-86-91
11. Centers for Disease Control and Prevention. Pneumococcal vaccine timing for adults. 2022. URL: https://www.cdc.gov/vaccines/vpd/pneumo/downloads/pneumo-vaccine-timing.pdf. (Accessed: 10th January 2023).
12. Chuchalin AG, Briko NI, Avdeev SN, Belevskiy AS, Bilichenko TN, Demko IV, et al. Federal clinical guidelines on preventive vaccination against pneumococcal infections in adults. Pulmonologiya. 2019;29(1):19-34 (In Russ.). doi: 10.18093/0869-0189-2019-29-1-19-34
13. Belov BS, Muravyeva NV, Tarasova GM, Baranova MM, Sergeeva MS, Cherkasova MV, et al. Pneumococcal vaccination in rheumatic diseases: 10 years of application experience at the V.A. Nasonova Research Institute of Rheumatology. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2022; 60(3):261-266 (In Russ.). doi: 10.47360/1995-4484-2022-261-266
14. Furer V, Rondaan C, Heijstek MW, Agmon-Levin N, van Assen S, Bijl M, et al. 2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis. 2020;79(1):39-52. doi: 10.1136/annrheumdis-2019-215882
15. Centers for Disease Control and Prevention. Use of 15-valent pneumococcal conjugate vaccine and 20-valent pneumococcal conjugate vaccine among U.S. adults: Updated recommendations of the Advisory Committee on Immunization Practices – United States, 2022. URL: https://www.cdc.gov/mmwr/volumes/71/wr/mm7104a1.htm?s_cid=mm7104a1_w (Accessed: 10th January 2023).
16. Yun H, Yang S, Chen L, Xie F, Winthrop K, Baddley JW, et al. Risk of herpes zoster in autoimmune and inflammatory diseases: Implications for vaccination. Arthritis Rheumatol. 2016;68(9):2328-2337. doi: 10.1002/art.39670
17. Kwan A, Rayes HA, Lazova T, Anderson N, Bonilla D, Su J, et al. Herpes zoster in SLE: Prevalence, incidence and risk factors. Lupus Sci Med. 2022;9(1):e000574. doi: 10.1136/lupus-2021-000574
18. Vink P, Ramon Torrell JM, Sanchez Fructuoso A, Kim SJ, Kim SI, Zaltzman J, et al.; Z-041 Study Group. Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in chronically immunosuppressed adults following renal transplant: A phase 3, randomized clinical trial. Clin Infect Dis. 2020;70(2): 181-190. doi: 10.1093/cid/ciz177
19. Bastidas A, de la Serna J, El Idrissi M, Oostvogels L, Quittet P, López-Jiménez J, et al.; ZOE-HSCT Study Group Collaborators. Effect of recombinant zoster vaccine on incidence of herpes zoster after autologous stem cell transplantation: A randomized clinical trial. JAMA. 2019;322(2):123-133. doi: 10.1001/jama.2019.9053
20. Dagnew AF, Ilhan O, Lee WS, Woszczyk D, Kwak JY, Bowcock S, et al.; Zoster-039 Study Group. Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in adults with haematological malignancies: A phase 3, randomised, clinical trial and post-hoc efficacy analysis. Lancet Infect Dis. 2019;19(9):988-1000. doi: 10.1016/S1473-3099(19)30163-X
21. Lenfant T, Jin Y, Kirchner E, Hajj-Ali RA, Calabrese LH, Calabrese C. Safety of recombinant zoster vaccine: A retrospective study of 622 rheumatology patients. Rheumatology. 2021;60(11):5149-5157. doi: 10.1093/rheumatology/keab139
22. Feldman CH, Liu J, Feldman S, Solomon DH, Kim SC. Risk of high-grade cervical dysplasia and cervical cancer in women with systemic lupus erythematosus receiving immunosuppressive drugs. Lupus. 2017;26(7):682-689. doi: 10.1177/0961203316672928
23. Kim SC, Schneeweiss S, Liu J, Karlson EW, Katz JN, Feldman S, et al. Biologic disease-modifying antirheumatic drugs and risk of high-grade cervical dysplasia and cervical cancer in rheumatoid arthritis: A cohort study. Arthritis Rheumatol. 2016;68(9):2106-2113. doi: 10.1002/art.39689
24. Dhar JP, Essenmacher L, Dhar R, Magee A, Ager J, Sokol RJ. The safety and immunogenicity of Quadrivalent HPV (qHPV) vaccine in systemic lupus erythematosus. Vaccine. 2017;35(20):2642-2646. doi: 10.1016/j.vaccine.2017.04.001
25. Mok CC, Ho LY, Fong LS, To CH. Immunogenicity and safety of a quadrivalent human papillomavirus vaccine in patients with systemic lupus erythematosus: A case-control study. Ann Rheum Dis. 2013;72(5):659-664. doi: 10.1136/annrheumdis-2012-201393
26. Adler S, Krivine A, Weix J, Rozenberg F, Launay O, Huesler J, et al. Protective effect of A/H1N1 vaccination in immune-mediated disease – A prospectively controlled vaccination study. Rheumatology (Oxford). 2012;51(4):695-700. doi: 10.1093/rheumatology/ker389
27. Ribeiro AC, Guedes LK, Moraes JC, Saad CG, Aikawa NE, Calich AL, et al. Reduced seroprotection after pandemic H1N1 influenza adjuvant-free vaccination in patients with rheumatoid arthritis: Implications for clinical practice. Ann Rheum Dis. 2011;70(12):2144-2147. doi: 10.1136/ard.2011.152983
28. Park JK, Lee MA, Lee EY, Song YW, Choi Y, Winthrop KL, et al. Effect of methotrexate discontinuation on efficacy of seasonal influenza vaccination in patients with rheumatoid arthritis: A randomised clinical trial. Ann Rheum Dis. 2017;76(9):1559-1565. doi: 10.1136/annrheumdis-2017-211128
29. Park JK, Lee YJ, Shin K, Ha YJ, Lee EY, Song YW, et al. Impact of temporary methotrexate discontinuation for 2 weeks on immunogenicity of seasonal influenza vaccination in patients with rheumatoid arthritis: A randomised clinical trial. Ann Rheum Dis. 2018;77(6):898-904. doi: 10.1136/annrheumdis-2018-213222
30. Naumtseva MS, Belov BS, Aleksandrova EN, Tarasova GM, Novikov AA, Karateev DE, et al. Immunogenicity and safety of 23-valent polysaccharide pneumococcal vaccine in patients with rheumatoid arthritis: Results of a two-year followup study. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2016;54(6):674-680 (In Russ.). doi: 10.14412/1995-4484-2016-674-680
31. Bukhanova DV, Belov BS, Tarasova GM, Erdes S, Dubinina TV, Lukina GV, et al. Efficacy, safety and immunogenicity of a trivalent inactivated split influenza vaccine in patients with rheumatic diseases. Medical Council. 2018;(12):106-110 (In Russ.). doi: 10.21518/2079-701X-2018-12-106-110
32. Tarasova GM, Belov BS, Cherkasova MV, Aseyeva YeA, Reshetnyak TM, Popkova TV, et al. Immunization with 23-valent polysaccharide pneumococcal vaccine in patients with systemic lupus erythematosus receiving combined immunosuppressive therapy. Effective Pharmacotherapy. 2021;17(36):6-12 (In Russ.). doi: 10.33978/2307-3586-2021-17-36-6-12
33. Tarasova G, Egorova O, Reshetnyak T, Belov B. Tolerability and safety of 23-valent polysaccharide pneumococcal vaccine in patients with systemic vasculitis, preliminary results. Ann Rheum Dis. 2022; 81(Suppl 1):1435. doi: 10.1136/annrheumdis-2022-eular.1487
34. Valim V, Machado KLLL, Miyamoto ST, Pinto AD, Rocha PCM, Serrano EV, et al. Planned yellow fever primary vaccination is safe and immunogenic in patients with autoimmune diseases: A prospective non-interventional study. Front Immunol. 2020;11:1382. doi: 10.3389/fimmu.2020.01382
35. Wieten RW, Jonker EF, Pieren DK, Hodiamont CJ, van Thiel PP, van Gorp EC, et al. Comparison of the PRNT and an immune fluorescence assay in yellow fever vaccines receiving immunosuppressive medication. Vaccine. 2016;34(10):1247-1251. doi: 10.1016/j.vaccine.2016.01.037
36. Heijstek MW, Pileggi GC, Zonneveld-Huijssoon E, Armbrust W, Hoppenreijs EP, Uiterwaal CS, et al. Safety of measles, mumps and rubella vaccination in juvenile idiopathic arthritis. Ann Rheum Dis. 2007;66(10):1384-1387. doi: 10.1136/ard.2006.063586
37. Curtis JR, Cofield SS, Bridges SL Jr, Bassler J, Deodhar A, Ford TL, et al. The safety and immunologic effectiveness of the live varicella-zoster vaccine in patients receiving tumor necrosis factor inhibitor therapy: A randomized controlled trial. Ann Intern Med. 2021;174(11):1510-1518. doi: 10.7326/M20-6928
38. Rubin LG, Levin MJ, Ljungman P, Davies EG, Avery R, Tomblyn M, et al.; Infectious Diseases Society of America. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis. 2014;58(3):e44-e100. doi: 10.1093/cid/cit684
39. Papp KA, Haraoui B, Kumar D, Marshall JK, Bissonnette R, Bitton A, et al. Vaccination guidelines for patients with immunemediated disorders on immunosuppressive therapies. J Cutan Med Surg. 2019;23(1):50-74. doi: 10.1177/1203475418811335
40. Centers for Disease Control and Prevention. Altered immunocompetence. URL: https://www.cdc.gov/vaccines/hcp/acip-recs/generalrecs/immunocompetence.html (Accessed 10th January 2023).
41. Beaulieu DB, Ananthakrishnan AN, Martin C, Cohen RD, Kane SV, Mahadevan U. Use of biologic therapy by pregnant women with inflammatory bowel disease does not affect infant response to vaccines. Clin Gastroenterol Hepatol. 2018;16(1):99-105. doi: 10.1016/j.cgh.2017.08.041
42. Chiarella-Redfern H, Lee S, Jubran B, Sharifi N, Panaccione R, Constantinescu C, et al. Suboptimal vaccination administration in mothers with inflammatory bowel disease and their biologicexposed infants. Inflamm Bowel Dis. 2022;28(1):79-86. doi: 10.1093/ibd/izab033
43. Lee KE, Jung SA, Park SH, Moon CM, Shim SY, Kim ES, et al. Influence of anti-tumor necrosis factor-alpha therapy to pregnant inflammatory bowel disease women and their children’s immunity. Intest Res. 2019;17(2):237-243. doi: 10.5217/ir.2018.00071
44. Ben-Horin S, Yavzori M, Kopylov U, Picard O, Fudim E, Eliakim R, et al. Detection of infliximab in breast milk of nursing mothers with inflammatory bowel disease. J Crohns Colitis. 2011;5(6):555-558. doi: 10.1016/j.crohns.2011.05.006
45. Ling J, Koren G. Challenges in vaccinating infants born to mothers taking immunoglobulin biologicals during pregnancy. Expert Rev Vaccines. 2016;15(2):239-256. doi: 10.1586/14760584.2016.1115351
46. Arad U, Tzadok S, Amir S, Mandelboim M, Mendelson E, Wigler I, et al. The cellular immune response to influenza vaccination is preserved in rheumatoid arthritis patients treated with rituximab. Vaccine. 2011;29(8):1643-1648. doi: 10.1016/j.vaccine.2010.12.072
47. Westra J, van Assen S, Wilting KR, Land J, Horst G, de Haan A, et al. Rituximab impairs immunoglobulin (Ig)M and IgG (subclass) responses after influenza vaccination in rheumatoid arthritis patients. Clin Exp Immunol. 2014;178(1):40-47. doi: 10.1111/cei.12390
48. Koch J, Harder T, von Kries R, Wichmann O. Risk of intussusception after rotavirus vaccination. Dtsch Arztebl Int. 2017;114(15):255-262. doi: 10.3238/arztebl.2017.0255
49. Centers for Disease Control and Prevention. Timing and spacing of immunobiologics. URL: https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/timing.html#:_:text=Two%20or%20more%20injectable%20or,the%20potential%20risk%20for%20interference (Accessed: 10th January 2023).
Review
For citations:
Belov B.S., Muravyeva N.V., Nasonov E.L. Vaccination for rheumatic diseases: Current issues (based on ACR guidelines). Rheumatology Science and Practice. 2023;61(2):151-157. (In Russ.) https://doi.org/10.47360/1995-4484-2023-151-157
Views:
794
Email this article 